McCormick S U
New York Eye and Ear Infirmary, New York 10003, USA.
J Oral Maxillofac Surg. 1996 May;54(5):583-7; discussion 588-9. doi: 10.1016/s0278-2391(96)90637-0.
This study evaluated the use of intralesional vinblastine injections for the treatment of the intraoral lesions of Kaposi's sarcoma.
Eighteen patients were treated with up to three intralesional injections of 0.1 mg/cc vinblastine.
All lesions responded to the local injections; 40% required one injection; 31%, two injections; and 29%, three injections. Large, exophytic lesions usually required the multiple injections. No complications were encountered, and the patients tolerated the protocol well. Ten patients were followed for 24 months. Eight died of their general disease during this period. Four patients developed new intraoral lesions, which were treated with, and responded favorably to, the three-injection protocol.
Intralesional vinblastine injections are an effective and useful treatment alternative for human immunodeficiency virus (HIV)-associated intraoral Kaposi's sarcoma.